A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)
A Long-Term Extension Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Patients With Graves' Disease
Sponsor: Immunovant Sciences GmbH
Listed as NCT07286006, this observational or N/A phase trial focuses on Graves' Disease and remains ongoing. Sponsored by Immunovant Sciences GmbH, it has been updated 3 times since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
3 versions recorded-
Apr 28, 2026 — Present [daily]
Enrolling By Invitation
Phase: PHASE2 → None
-
Feb 2026 — Apr 2026 [monthly]
Enrolling By Invitation PHASE2
Status: Not Yet Recruiting → Enrolling By Invitation
-
Jan 2026 — Feb 2026 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
This is a long-term extension study that will rollover participants completing feeder studies IMVT-1402-2502 (NCT06727604) or IMVT-1402-2503 (NCT07018323) to evaluate the efficacy and safety of IMVT-1402 in adult participants with GD. Eligible participants will be assigned to 1 of 3 study groups (Groups A, B and C) based on their GD status at the completion of their respective feeder study.
Contact Information
- Immunovant Sciences GmbH
For direct contact, visit the study record on ClinicalTrials.gov .